Reduction in HCV Incidence Among Injection Drug Users Attending Needle and Syringe Programs in Australia: a Linkage Study

Overview

Journal Am J Public Health

Specialty Public Health

Date 2013 Jun 15

PMID 23763399

Citations 27

Authors

Jenny Iversen

Handan Wand

Libby Topp

John Kaldor

Lisa Maher

Affiliations

Soon will be listed here.

Abstract

Objectives: We examined trends in HCV incident infection among injection drug users (IDUs) attending needle and syringe programs (NSPs) in Australia in 1995 to 2010.

Methods: We created a passive retrospective cohort of 724 IDUs who tested negative for HCV antibodies by a simple deterministic method linking partial identifiers to find repeat respondents in annual cross-sectional serosurveillance.

Results: We identified 180 HCV seroconversions over the study period, for a pooled incidence density of 17.0 per 100 person-years (95% confidence interval [CI] = 14.68, 19.66). Incidence density declined, from a high of 30.8 per 100 person-years (95% CI = 21.3, 44.6) in 2003 to a low of 4.0 (95% CI = 1.3, 12.3) in 2009.

Conclusions: A decline in HCV incidence among Australian IDUs attending NSPs coincided with considerable expansion of harm reduction programs and a likely reduction in the number of IDUs, associated with significant changes in drug markets. Our results demonstrate the capacity of repeat cross-sectional serosurveillance to monitor trends in HCV incidence and provide a platform from which to assess the impact of prevention and treatment interventions.

Citing Articles

Incidence of HIV and hepatitis C virus among people who inject drugs, and associations with age and sex or gender: a global systematic review and meta-analysis.

Artenie A, Stone J, Fraser H, Stewart D, Arum C, Lim A Lancet Gastroenterol Hepatol. 2023; 8(6):533-552.

PMID: 36996853 PMC: 10817215. DOI: 10.1016/S2468-1253(23)00018-3.

Comprehensive needle and syringe program and opioid agonist therapy reduce HIV and hepatitis c virus acquisition among people who inject drugs in different settings: A pooled analysis of emulated trials.

Van Santen D, Lodi S, Dietze P, van den Boom W, Hayashi K, Dong H Addiction. 2023; 118(6):1116-1126.

PMID: 36710474 PMC: 10175130. DOI: 10.1111/add.16147.

Uptake of COVID-19 vaccination among people who inject drugs.

Iversen J, Wand H, Kemp R, Bevan J, Briggs M, Patten K Harm Reduct J. 2022; 19(1):59.

PMID: 35655217 PMC: 9162792. DOI: 10.1186/s12954-022-00643-3.

Methods and indicators to validate country reductions in incidence of hepatitis C virus infection to elimination levels set by WHO.

Artenie A, Luhmann N, Lim A, Fraser H, Ward Z, Stone J Lancet Gastroenterol Hepatol. 2022; 7(4):353-366.

PMID: 35122713 PMC: 10644895. DOI: 10.1016/S2468-1253(21)00311-3.

Care Facilitation Advances Movement Along the Hepatitis C Care Continuum for Persons With Human Immunodeficiency Virus, Hepatitis C, and Substance Use: A Randomized Clinical Trial (CTN-0064).

Metsch L, Feaster D, Gooden L, Masson C, Perlman D, Jain M Open Forum Infect Dis. 2021; 8(8):ofab334.

PMID: 34377726 PMC: 8339611. DOI: 10.1093/ofid/ofab334.

References

Nelson P, Mathers B, Cowie B, Hagan H, Des Jarlais D, Horyniak D . Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011; 378(9791):571-83. PMC: 3285467. DOI: 10.1016/S0140-6736(11)61097-0. View

Alter H, Liang T . Hepatitis C: the end of the beginning and possibly the beginning of the end. Ann Intern Med. 2012; 156(4):317-8. PMC: 3480337. DOI: 10.7326/0003-4819-156-4-201202210-00014. View

Kellogg T, Loeb L, Dilley J, Adler B, Louie B, McFarland W . Comparison of three methods to measure HIV incidence among persons seeking voluntary, anonymous counseling and testing. J Acquir Immune Defic Syndr. 2005; 39(1):112-20. DOI: 10.1097/01.qai.0000144444.44518.a3. View

Day C, Degenhardt L, Gilmour S, Hall W . Effects of reduction in heroin supply on injecting drug use: analysis of data from needle and syringe programmes. BMJ. 2004; 329(7463):428-9. PMC: 514203. DOI: 10.1136/bmj.38201.410255.55. View

Ly K, Xing J, Klevens R, Jiles R, Ward J, Holmberg S . The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012; 156(4):271-8. DOI: 10.7326/0003-4819-156-4-201202210-00004. View

MacDonald M, Wodak A, Ali R, Crofts N, Cunningham P, Dolan K . HIV prevalence and risk behaviour in needle exchange attenders: a national study. The Collaboration of Australian Needle Exchanges. Med J Aust. 1997; 166(5):237-40. View

van den Berg C, Smit C, Bakker M, Geskus R, Berkhout B, Jurriaans S . Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users. Eur J Epidemiol. 2007; 22(3):183-93. PMC: 2781102. DOI: 10.1007/s10654-006-9089-7. View

Kent C, Chaw J, Kohn R, Chen Y, Klausner J . Studies relying on passive retrospective cohorts developed from health services data provide biased estimates of incidence of sexually transmitted infections. Sex Transm Dis. 2004; 31(10):596-600. DOI: 10.1097/01.olq.0000140011.93104.32. View

Aitken C, Lewis J, Tracy S, Spelman T, Bowden D, Bharadwaj M . High incidence of hepatitis C virus reinfection in a cohort of injecting drug users. Hepatology. 2008; 48(6):1746-52. DOI: 10.1002/hep.22534. View

10.

Kaye S, Darke S . A comparison of the harms associated with the injection of heroin and amphetamines. Drug Alcohol Depend. 2000; 58(1-2):189-95. DOI: 10.1016/s0376-8716(99)00102-7. View

11.

Topp L, Day C, Degenhardt L . Changes in patterns of drug injection concurrent with a sustained reduction in the availability of heroin in Australia. Drug Alcohol Depend. 2003; 70(3):275-86. DOI: 10.1016/s0376-8716(03)00013-9. View

12.

Lavanchy D . Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2010; 17(2):107-15. DOI: 10.1111/j.1469-0691.2010.03432.x. View

13.

Maher L, Jalaludin B, Chant K, Jayasuriya R, Sladden T, Kaldor J . Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction. 2006; 101(10):1499-508. DOI: 10.1111/j.1360-0443.2006.01543.x. View

14.

Aceijas C, Rhodes T . Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy. 2007; 18(5):352-8. DOI: 10.1016/j.drugpo.2007.04.004. View

15.

Razali K, Thein H, Bell J, Cooper-Stanbury M, Dolan K, Dore G . Modelling the hepatitis C virus epidemic in Australia. Drug Alcohol Depend. 2007; 91(2-3):228-35. DOI: 10.1016/j.drugalcdep.2007.05.026. View

16.

Dietze P, FitzGerald J . Interpreting changes in heroin supply in Melbourne: droughts, gluts or cycles?. Drug Alcohol Rev. 2002; 21(3):295-303. DOI: 10.1080/0959523021000002778. View

17.

Lok A, Pawlotsky J . Viral hepatitis at a crossroad. Gastroenterology. 2012; 142(6):1261-3. DOI: 10.1053/j.gastro.2012.03.007. View

18.

Levy M, Treloar C, McDonald R, Booker N . Prisons, hepatitis C and harm minimisation. Med J Aust. 2007; 186(12):647-9. DOI: 10.5694/j.1326-5377.2007.tb01085.x. View

19.

Bryant J, Topp L, Hopwood M, Iversen J, Treloar C, Maher L . Is point of access to needles and syringes related to needle sharing? Comparing data collected from pharmacies and needle and syringe programs in south-east Sydney. Drug Alcohol Rev. 2010; 29(4):364-70. DOI: 10.1111/j.1465-3362.2009.00154.x. View

20.

Hagan H, Pouget E, Des Jarlais D . A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infect Dis. 2011; 204(1):74-83. PMC: 3105033. DOI: 10.1093/infdis/jir196. View